Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin efficiency in thalassemia
IRCT20211202053252N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of erythropoietin in Beta-thalassemia minor, breast cancer, colon cancer and 4 more, sponsored by Babol University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
erythropoietin
03
Conditions
Beta-thalassemia minorbreast cancercolon cancerrectal cancergastric cancer (GC)
Beyond the preview
Go deeper on IRCT20211202053252N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211202053252N1.